Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats

被引:34
作者
Lee, Dae Y.
Shin, Hyun S.
Bae, Soo K.
Lee, Myung G.
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
关键词
omeprazole; CYP isozymes; enzyme inducers and inhibitors; pharmacokinetics; rats;
D O I
10.1002/bdd.502
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of experiments using various inducers and inhibitors of the hepatic microsomal cytochrome P450 (CYP) isozymes were conducted to find CYP isozymes responsible for the metabolism of omeprazole in male Sprague-Dawley rats. Omeprazole, 20mg/kg, was administered intravenously. In rats pretreated with SKF 525-A (a nonspecific CYP isozyme inhibitor in rats), the time-averaged nonrenal clearance (Cl-nr) Was significantly slower (77.1% decrease) than that in untreated rats. This indicated that omeprazole is metabolized via CYP isozymes in rats. Hence, rats were pretreated with various enzyme inducers and inhibitors. In rats pretreated with 3-methyl-cholanthrene and dexamethasone (main inducers of CYP1A1/2 and 3A1/2 in rats, respectively), the Clnr values were significantly faster (43.8% and 26.3% increase, respectively). In rats pretreated with troleandomycin and quinine (main inhibitors of CYP3A1/2 and 2D1 in rats, respectively), the Cl-nr values were significantly slower (20.9% and 12.9% decrease, respectively). However, the Cl-nr values were not significantly different in rats pretreated with orphenadrine, isoniazid and sulfaphenazole (main inducers of CYP2B1/2 and 2E1, and a main inhibitor of 2C11, respectively, in rats) compared with those of respective control rats. The above data suggested that omeprazole could be mainly metabolized via CYP1A1/2, 3A1/2 and 2D1 in male rats. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:209 / 218
页数:10
相关论文
共 42 条
[11]   Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: Complete or partial restoration by cysteine or methionine supplementation [J].
Cho, MK ;
Kim, YG ;
Lee, MG ;
Kim, SG .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 372 (01) :150-158
[12]   EFFECTS OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF FUROSEMIDE IN RATS [J].
CHOI, YM ;
KIM, SH ;
LEE, MG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (07) :638-642
[13]  
CONNEY AH, 1971, FUNDAMENTALS DRUG ME, P269
[14]  
CORREIA MA, 1995, CYTOCHROME P450 STRU, P607
[15]   PHARMACOKINETICS OF DIAZEPAM FOLLOWING MULTIPLE-DOSE ORAL-ADMINISTRATION TO HEALTHY HUMAN SUBJECTS [J].
EATMAN, FB ;
COLBURN, WA ;
BOXENBAUM, HG ;
POSMANTER, HN ;
WEINFELD, RE ;
RONFELD, R ;
WEISSMAN, L ;
MOORE, JD ;
GIBALDI, M ;
KAPLAN, SA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05) :481-494
[16]  
Gibaldi M, 1982, Pharmacokinetics, V15
[17]   IRREVERSIBLE INACTIVATION OF RAT GASTRIC (H+-K+)-ATPASE INVIVO BY OMEPRAZOLE [J].
IM, WB ;
BLAKEMAN, DP ;
DAVIS, JP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 126 (01) :78-82
[18]   Advanced method for determination of omeprazole in plasma by HPLC [J].
Kang, WK ;
Kim, DS ;
Kwon, KI .
ARCHIVES OF PHARMACAL RESEARCH, 1999, 22 (01) :86-88
[19]  
Karam WG, 1996, DRUG METAB DISPOS, V24, P1081
[20]   Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant nagase analbuminemic rats [J].
Kim, EJ ;
Lee, AK ;
Kim, SH ;
Kim, SG ;
Lee, MG .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (02) :194-201